The earliest warnings appear in what patients understand, expect, and can sustain, long before they surface in screening, retention, or completion reports.The Readiness Gap examines those signals through behavioral science, real-world data, and frontline experience.When readiness becomes visible, preventable failure can be addressed before the trial pays for it.
Clinical trial eligibility does not predict participation, retention, or completion. Patient readiness is the missing variable behind trial performance.
Read article →A 13-part series by Andy Proctor
Thirteen behavioral-science essays on how patients understand, evaluate, enter, sustain, and complete clinical trial participation. Each article translates established evidence into practical implications for patient readiness and trial execution.
Clinical trial decisions depend on understanding, emotion, trust, feasibility, and social context. Learn how patient readiness supports informed participation.
Read essay →Fear, hope, and uncertainty shape how patients process clinical trial information. Learn how emotionally intelligent design supports informed consent.
Read essay →Status quo bias, loss aversion, optimism, and ambiguity influence clinical trial decisions. Learn how better design supports informed choice.
Read essay →Fear and uncertainty can be rational responses to clinical trial participation. Learn how readiness support addresses risk without minimizing it.
Read essay →Health literacy and cognitive load shape consent, adherence, and completion. Learn why readiness education must extend beyond the consent form.
Read essay →Every clinical trial experience shapes decisions. Learn how to reduce friction while protecting informed consent, autonomy, and voluntariness.
Read essay →Framing, anchoring, and priming shape how patients interpret clinical trial information. Learn how to design truthful, balanced first encounters.
Read essay →More clinical trial information does not always create more understanding. Learn how choice overload and information avoidance affect readiness.
Read essay →Patients experience trial burden now while many benefits remain uncertain or distant. Learn how temporal discounting and practical friction affect participation.
Read essay →Physicians, coordinators, caregivers, and peers shape clinical trial trust. Learn why consistent human communication matters more than polished materials.
Read essay →Patients rarely decide or complete a clinical trial alone. Learn how caregivers, peers, clinicians, and community context shape readiness.
Read essay →Eligible patients may decline a clinical trial because participation is unclear, infeasible, unsupported, or misaligned with their lives.
Read essay →Participants want closure after the final visit. Learn how plain-language results and post-trial communication strengthen trust in research.
Read essay →A 10-part series by Rebecca Schelkun and Mike Burton
Ten evidence-grounded essays on the decisions patients make from first awareness through sustained participation, and the readiness conditions that make each transition understandable, voluntary, and feasible.
Map the clinical trial patient decision journey from awareness through sustained participation, with readiness questions for every transition.
Read essay →Clinical trial outreach begins the informed-consent process. Learn how ethical awareness campaigns create relevance without promising outcomes.
Read essay →Learn how clinical trial misinformation shapes patient decisions and how trusted, empathetic correction supports informed participation.
Read essay →Personalized clinical trial matching should explain relevance, burden, and uncertainty, not simply identify medical eligibility.
Read essay →Patient preferences can improve clinical trial feasibility when they shape burden, endpoints, communication, and support before recruitment begins.
Read essay →Decentralized clinical trial elements can improve access, but only when technology, home demands, privacy, and local support fit the patient.
Read essay →Understand reimbursement, compensation, incentives, and ethical safeguards for clinical trial participant payment and voluntary consent.
Read essay →Culturally responsive clinical trials align language, trust, access, staff, family roles, and community context with equitable participation.
Read essay →Learn when clinical trial recontact may be appropriate and how to protect refusal, autonomy, voluntariness, and permanent opt-out.
Read essay →Use patient journey metrics to detect comprehension, trust, feasibility, and handoff risk before enrollment and retention reports move.
Read essay →A 9-part series by Rebecca Schelkun and Mike Burton
Nine evidence-grounded essays on the knowledge, confidence, capability, support, and participation conditions that turn informed choice into action and sustain it through the trial.
Learn what patient activation means in clinical trials and how knowledge, confidence, capability, and support shape informed participation.
Read essay →See how task-specific confidence affects clinical trial decisions, participation behavior, and the support patients need to continue.
Read essay →Clinical trial decision support should reduce cognitive friction and preserve voluntary choice, not use behavioral science to push enrollment.
Read essay →Patient stories can clarify participation, but ethical use requires balance, consent, context, and protection against implied outcomes.
Read essay →Transparent communication explains burden, uncertainty, alternatives, payment, and support before patients commit.
Read essay →Digital tools support patient activation when they reduce burden, preserve context, protect choice, and provide human escalation.
Read essay →Patient education cannot compensate for avoidable protocol burden. Trial design and feasibility shape whether activation can hold.
Read essay →Patient activation changes during a trial. Expectation alignment, support, and early signals help protect sustained participation.
Read essay →Post-trial communication closes the participation loop, returns value to patients, and creates more credible research partnerships.
Read essay →Recruitment and retention fail for reasons that rarely surface in feasibility. This is the master map of the 19 patient frictions behind them.
Read article →Eligible, willing patients still decline at the consent table. Six behavioral frictions explain why, and what to do about each.
Read article →The strongest predictors of who enrolls and stays often have nothing to do with the protocol. Five social frictions decide who can participate.
Read article →A patient rarely decides or completes a trial alone. The household can strengthen participation or quietly end it.
Read article →A signature starts retention risk. Four frictions behind mid-study dropout are often visible before the patient leaves.
Read article →Clinical trials have become better at finding medically eligible patients. What they still struggle to understand is whether those patients are prepared to engage, consent, persist, and complete.
Read article →How cognitive biases, decision-making patterns, and behavioral economics shape trial participation and persistence.
Protocol structures, inclusion and exclusion criteria, visit burden, and operational requirements that create or prevent readiness failure.
Site training, resource constraints, patient flow, staff readiness, and operational metrics that predict trial outcomes.
What trials measure, why traditional metrics miss readiness failure, and which indicators actually predict success.
Every week, The Readiness Gap delivers one substantive article exploring the hidden forces that determine clinical trial success.
The readiness gap is the space between eligibility and actual ability to participate successfully. A patient can meet all inclusion criteria and still fail because their life circumstances, support systems, understanding, or capacity do not align with trial demands.
Traditional metrics focus on enrollment volume. Readiness metrics focus on sustainability. They answer: Who will complete? Why do participants drop out? What operational factors predict success? This shifts accountability from recruitment to retention and completion.
This blog is written for clinical operations leaders, trial designers, site managers, sponsors, CROs, patient experience teams, and anyone frustrated by preventable trial failures. If you work where eligibility is easy but completion is hard, this is for you.
We publish one substantive article every week. Each article is five to ten minutes of reading and draws on real trial data, behavioral science research, and operator experience.
No. While Jumo's PRISM platform is built on readiness principles, The Readiness Gap explores readiness challenges, behavioral science, and operational insights independent of any single solution. We believe the category matters more than any vendor.
Yes. Email readiness@jumohealth.com with your idea. We read every submission and have written several articles based on operator and sponsor input.
CORE is Jumo Health's readiness education system. It prepares patients, caregivers, families, and sites with the understanding required to make and sustain informed participation decisions. PRISM measures and governs readiness across the trial lifecycle.
Readiness failures hit underrepresented populations hardest. When trials are designed without assessing social determinants, health literacy, or community barriers, they systematically exclude already-marginalized groups. Readiness is an equity issue.
In two days, you get three execution diagnostics on your program.
How likely each eligible patient cluster is to activate, persist, and complete, before any intervention.
The barriers most likely to suppress activation, enrollment, and completion in each cluster, and how to mitigate them.
Which clusters to target, which barriers to address, which interventions to deploy, and what completion lift to expect.